September 2015 - €2.7 million awarded by the EC

OncoMark are awarded €2.7 million by the European Commission to develop a diagnostic assay for breast cancer

OncoMark are pleased to announce they have been awarded €2.7 million by the European Commission, for the commercial development of a new Diagnostic test for breast cancer patients. This award will fund the development and commercialisation of OncoMasTR, a novel prognostic assay for early stage breast cancer that will reduce the number of breast cancer patients receiving unnecessary chemotherapy.